170 related articles for article (PubMed ID: 24388410)
41. Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions.
Starling N; Cunningham D
Curr Opin Oncol; 2004 Jul; 16(4):385-90. PubMed ID: 15187895
[TBL] [Abstract][Full Text] [Related]
42. Immunotherapy of cancer in 2012.
Kirkwood JM; Butterfield LH; Tarhini AA; Zarour H; Kalinski P; Ferrone S
CA Cancer J Clin; 2012; 62(5):309-35. PubMed ID: 22576456
[TBL] [Abstract][Full Text] [Related]
43. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
Yang H; Yu AP; Wu EQ; Yim YM; Yu E
J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
[TBL] [Abstract][Full Text] [Related]
44. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer.
Thornton AD; Ravn P; Winslet M; Chester K
Br J Surg; 2006 Dec; 93(12):1456-63. PubMed ID: 17115389
[TBL] [Abstract][Full Text] [Related]
45. [Advances in the treatment of metastatic colorectal cancer with bevacizumab].
Longo F; Mansueto G
Tumori; 2006; 92(5):suppl 1-12. PubMed ID: 17168449
[No Abstract] [Full Text] [Related]
46. Bevacizumab vs EGFR antibodies in metastatic colorectal cancer.
Venook AP
Clin Adv Hematol Oncol; 2015 Feb; 13(2):90-2. PubMed ID: 25774477
[No Abstract] [Full Text] [Related]
47. [Impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis].
Assenat E; Ychou M
Bull Cancer; 2009 Dec; 96 Suppl():S41-6. PubMed ID: 20034869
[TBL] [Abstract][Full Text] [Related]
48. [Role of angiogenesis inhibitors in the treatment of colorectal cancer].
Bodoky G
Magy Onkol; 2007; 51(2):139-44. PubMed ID: 17660870
[TBL] [Abstract][Full Text] [Related]
49. Vascular biology support for the use of bevacizumab in colorectal cancer.
Doggrell SA
Expert Opin Investig Drugs; 2004 Jun; 13(6):703-5. PubMed ID: 15174956
[TBL] [Abstract][Full Text] [Related]
50. The role of new agents in the treatment of colorectal cancer.
Ruiz de Erenchun F
Oncology; 2005; 68(2-3):162; author reply 162. PubMed ID: 16097096
[No Abstract] [Full Text] [Related]
51. Antiangiogenesis agents in colorectal cancer.
Hubbard J; Grothey A
Curr Opin Oncol; 2010 Jul; 22(4):374-80. PubMed ID: 20375894
[TBL] [Abstract][Full Text] [Related]
52. Bevacizumab and micrometastases: revisiting the preclinical and clinical rollercoaster.
Mountzios G; Pentheroudakis G; Carmeliet P
Pharmacol Ther; 2014 Feb; 141(2):117-24. PubMed ID: 24076268
[TBL] [Abstract][Full Text] [Related]
53. [Management of metastatic colorectal cancer].
Tournigand C; Bengrine-Lefevre L; Chibaudel B; de Gramont A
Rev Prat; 2010 Oct; 60(8):1103-7. PubMed ID: 21197743
[TBL] [Abstract][Full Text] [Related]
54. ASPECCT: panitumumab versus cetuximab for colorectal cancer.
Hawkes EA; Wong R
Lancet Oncol; 2014 Jul; 15(8):e302-3. PubMed ID: 24988927
[No Abstract] [Full Text] [Related]
55. ASPECCT: panitumumab versus cetuximab for colorectal cancer.
Sunakawa Y; Ichikawa W; Sasaki Y
Lancet Oncol; 2014 Jul; 15(8):e301-2. PubMed ID: 24988926
[No Abstract] [Full Text] [Related]
56. Novel approaches to advanced breast cancer: bevacizumab and lapatinib.
Mayer EL; Lin NU; Burstein HJ
J Natl Compr Canc Netw; 2007 Mar; 5(3):314-23. PubMed ID: 17439759
[TBL] [Abstract][Full Text] [Related]
57. Targeted therapies: Goldie-Coldman and bevacizumab beyond disease progression.
Giantonio BJ
Nat Rev Clin Oncol; 2009 Jun; 6(6):311-2. PubMed ID: 19483736
[TBL] [Abstract][Full Text] [Related]
58. Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions.
Goldberg RM; Hurwitz HI; Fuchs CS
Clin Adv Hematol Oncol; 2005 Dec; 3(12):1-10; quiz 11. PubMed ID: 16555433
[TBL] [Abstract][Full Text] [Related]
59. Panitumumab following disease progression on cetuximab in patients with metastatic colorectal cancer: a retrospective review.
Lau SC; Chung V; Lim D; Shibata S
J Oncol Pharm Pract; 2014 Apr; 20(2):83-7. PubMed ID: 23353714
[TBL] [Abstract][Full Text] [Related]
60. [Biotherapy in colorectal cancer].
Des Guetz G
J Chir (Paris); 2005; 142(5):291-6. PubMed ID: 16292207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]